Shopping Cart
- Remove All
- Your shopping cart is currently empty
DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | DTX-P7 is a peptide drug conjugate (PDC) composed of Docetaxel (DTX) and a heptapeptide (P7), which induces the unfolded protein response and subsequent apoptosis by degrading Hsp90. |
In vitro | DTX-P7 suppresses the expression of membrane-bound Hsp90 in a dose- and time-dependent manner, while no changes are observed at the mRNA level. It also enhances the phosphorylation of PERK and eIF2α; however, XBP-1 mRNA splicing is not observed upon exposure in A549 cells. |
In vivo | DTX-P7 administered to mice with A549 xenograft tumors (15/30 mg/kg, once weekly for 4 weeks) inhibits tumor growth in dormant/slow-proliferating A549/CD133+ cells by degrading DYRK1A and subsequently allowing cell cycle reentry. |
Molecular Weight | 1639.87 |
Formula | C84H118N8O25 |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.